TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04738513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical preparation technique
Description: Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Preparation technique
Description: Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
Study: NCT05942651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.
Description: The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals
Description: The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
Study: NCT05635734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 5 mg
Description: Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 10 mg
Description: Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 20 mg
Description: Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study: NCT05739994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
Study: NCT06581601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy, exercises
Description: An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
Study: NCT06043713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Receive IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Receptor-engineered T-cells
Description: Receive FHA11KRASG12V-TCR IV
Study: NCT04721418

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: 11C-UCB-J PET scan

Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: 11C-UCB-J PET scan
Study: NCT04628481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Oral ladarixin twice a day for 13 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo twice a day for 13 cycles
Study: NCT06058364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1 - Triglyceride
Description: Triglyceride (1 softgel each morning with a glass of water)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Intervention 2 - Placebo
Description: Placebo (1 softgel each morning with a glass of water)
Study: NCT05739994

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham theta burst transcranial magnetic stimulation
Description: Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
Study: NCT06643013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: 4 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: 4 weeks treatment
Study: NCT06643650

Intervention type: DIETARY_SUPPLEMENT
Intervention: CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML
Description: Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.

Intervention type: DIETARY_SUPPLEMENT
Intervention: CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML
Description: Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
Study: NCT04494698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duotherm VibraCool Back Device
Description: Active New multimodal pain device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS 8-channel unit
Description: LG Smart TENS unit
Study: NCT06335706

Intervention type: BEHAVIORAL
Intervention: Fit of underpants worn
Description: Tight or loose-fitted underpants

Intervention type: BEHAVIORAL
Intervention: Fit of underpants worn
Description: Tight or loose-fitted underpants
Study: NCT05607589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP213388
Description: immunosuppressant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06446648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
Study: NCT06189612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical reasoning based physiotherapy + cervical movement control training
Description: An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical reasoning based physiotherapy + orofacial movement control training
Description: An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical reasoning based physiotherapy + standard exercises
Description: A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
Study: NCT06284915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
Study: NCT05774275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: 200 mg, d1, q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
Study: NCT06207968

Intervention type: DEVICE
Intervention: Knee surgery with FH Ortho devices
Description: This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons.

Intervention type: DEVICE
Intervention: Knee surgery with FH Ortho devices
Description: This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons.
Study: NCT04733144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
Study: NCT04997837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study: NCT04733144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1,125 mg dexamethasone 4,5 mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1,125 mg dexamethasone 4,5 mg dexamethasone
Study: NCT06308965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel sparing technique
Description: Vessel sparing
Study: NCT05055453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPhonak Junior App
Description: The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Sky hearing aid
Description: A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
Study: NCT06086314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
Study: NCT04997837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium
Description: SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
Study: NCT05282459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib mesylat dose escalation
Description: Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
Study: NCT04890145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RW-Precision-Coupler
Description: Implantation of the RW-Precision-Coupler together with FMT-VORP 503
Study: NCT05063916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Given By IV
Study: NCT04949399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Injection
Study: NCT06086314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
Study: NCT04997837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy/Fx, 45-50.4 Gy
Study: NCT06021665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortetropin supplement
Description: Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cheese protein
Description: The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g
Study: NCT05591989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study: NCT06308965

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel ligation technique
Description: Vessel ligation
Study: NCT04234451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA acupuncture
Description: For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
Study: NCT06468865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (Dexcom® G7)
Description: Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
Study: NCT05216380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActivityLink
Description: ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot
Study: NCT04234451

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
Study: NCT04997837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
Study: NCT05012813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Essential Oils
Description: Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
Study: NCT06265441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected
Description: The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%
Description: The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
Study: NCT06086314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurorehabilitation program with functional reaching training without device.
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
Study: NCT05761743

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine and Blood Test
Description: Urine N-telopeptide and serum osteocalcin

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine and Blood Test
Description: Urine N-telopeptide and serum osteocalcin